PCV102 Comparison Of Exforge Hct Single Pill Combination And Amlodipine/Valsartan/Hydrochlorothiazide Free Combination: Adherence And Persistence  by Machnicki, G. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A119
with a history of recurrent hospitalizations. Interventions targeted at preventing 
HF hospitalizations would be beneficial.
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Objectives: The objective of the study is to estimate the follow up cost and its com-
ponents in patients subjected to pacemaker (PM) and implantable cardioverter-defi-
brillator (ICD) implantation. MethOds: A single-center, prospective, study which 
was conducted for one year’s reriod. In total, 464 consecutive patients were recruited 
(370 were subjected to PM implantation, from which 240 initials, 130 replacements 
and 94 to ICD implantation, from which 80 initials, 14 replacements). Resource 
data were assessed at patients’ enrolment in the study and at 6th and 12th months 
of patients’ follow-up. Then, the annual patients’ follow up costs were calculated 
using the bottom-up approach. Results: The annual follow up cost for the patients 
who were subjected to PM implantation (initial or replacement) was found to be: 
The mean direct health care cost (outpatient visits, hospitalizations, medication 
use and the cost of laboratory and imagining diagnostic examinations) was € 1.386 
(€ 1.069-€ 1.962). The mean direct non-health care cost was € 359 (€ 207-€ 551). Finally 
the mean indirect cost was € 71 (€ 70-€ 72). The mean (95% confidence interval) total 
annual follow-up cost for the patients who were subjected to PM implantation was 
€ 1.816 (€ 1.433– € 2.421). The annual follow up cost for the patients were subjected 
to ICD implantation (initial or replacement) was found to be: The mean direct health 
care cost (outpatient visits, hospitalizations, medication use and the cost of labo-
ratory and imagining diagnostic examinations) was 2.279 (1743-3.081). The mean 
direct non-health care costs was € 173 (€ 11-€ 386). Finally the mean indirect cost 
was € 367 (€ 72-€ 802). The mean (95% confidence interval) total annual follow-up 
cost for the patients who were subjected to ICD implantation was € 2.819 (€ 2.115–€ 
3.703). cOnclusiOns: The study provides unique data regarding the follow up 
cost and its separate components of patients with CRMDs in Greece. Moreover the 
findings indicate a low annual follow-up cost.
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Objectives: Limited evidence exists on the burden of chronic heart failure (CHF) 
in terms of reduced vs. preserved ejection fraction (HFrEF vs. HFpEF) and NYHA 
classification. This study aims to determine health care resource utilization asso-
ciated with CHF, both for HFrEF (≥ 45%) and HFpEF (< 40%) and according to NYHA 
class. MethOds: Retrospective analysis of a longitudinal population-based medical 
records database from southwestern Ontario was conducted. Records contain chart-
abstracted information such as diagnosis, physician visits and consultation notes. 
Data of adult patients with CHF diagnosed between Jan 1st, 2005 and Sept 31st, 2012 
with at least 1 year follow-up were included. Health care resources consumed by 
patients were identified in terms of hospitalizations, physician and emergency room 
visits and medical procedures. Data reported as mean values. Results: Records 
of 8,983 patients were included: 39% with HFrEF, 49% with HFpEF and 12% with an 
ejection fraction between 40-45%. The median follow-up duration was 51.6 months. 
Most patients were in NYHA class II (30%) or class III (34%) followed by class I (22%) 
and class IV (14%). In comparison to the HFpEF cohort, total hospitalizations (3.0 vs. 
4.2); including CHF hospitalizations (1.6 vs. 1.9), ER visits (2.1 vs. 3.1), GP visits (5.5 
vs. 6.1), specialist visits (3.0 vs. 3.2), lab tests (5.8 vs. 7.7) and medical procedures 
(3.9 vs. 4.1) were numerically higher for the HFrEF cohort. Among patients in NYHA 
class II-IV (N= 7006), hospitalizations (total: 4.5; CHF-related: 2.1) and lab tests (7.7) 
were numerically higher for class IV patients as was the frequency of GP visits (7.1) 
for class III patients. ER and specialist visits and medical procedures were similar 
across all NYHA classes. cOnclusiOns: In a real-world Canadian setting, patients 
with HFrEF and those in NYHA class III-IV seem to experience greater resource use 
which is consistent with the existing literature.
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Objectives: The objective of the present study is to estimate the procedure (or 
implantation) cost, which includes: the human resources cost, the implant and 
the supplies cost and the total hospitalization cost which includes: the procedure 
cost, the hospitalization cost, the laboratory and imaging diagnostic examination 
cost and the indirect cost, in patients subjected to pacemaker (PM) and implantable 
cardioverter-defibrillator (ICD) implantation. MethOds: A single-centre, prospec-
tive study was conducted for one year’s period. In total, 464 consecutive patients 
were recruited (370 were subjected to PM implantation initial or replacement and 94 
to ICD implantation initial or replacement). Resource data were assessed at patients’ 
enrolment in the study as well as during the procedure of implantation. Then, the 
components of the procedure cost and total hospitalization cost were calculated 
using the bottom-up approach. Results: The mean (95% confidence interval) pro-
cedure cost of PM and ICD implantation (including the costs of devices, electrodes, 
other supplies, and personnel’s time) was calculated to be € 1.803 (€ 1.758–€ 1.858) and 
€13.521 (€ 13.153–€13.892), respectively. The mean total hospitalization cost (includ-
ing procedure cost, hospitalization cost, cost of laboratory and imaging diagnostic 
examinations and the indirect cost attributed to productivity lost due to patient’s 
hospitalization) was € 3.926 (€ 3.711–€ 4.167) for PM and € 17.764 (€ 16.852–€ 18.692) for 
ICD. cOnclusiOns: These data revealed that although these devices are associ-
ated with a relatively high upfront cost, the total implantation cost for the society 
is relatively low compared with other countries. Therefore, implantation of such 
devices should be encouraged since these devices reduce the morbidity and mortal-
ity without a high economic burden to society.
CardioVasCUlar disorders – Patient-reported outcomes & Patient Prefer-
ence studies
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Objectives: Medication non-adherence is associated with worsening health out-
comes and higher medical costs. This study assessed the impact of a prescriber 
mailing intervention on adherence among 802,355 members enrolled in Medicare 
Part D prescription drug plans offered by a pharmacy benefit manager. MethOds: 
Non-adherent members in three drug classes – oral antidiabetics, statins and one 
class of antihypertensives (RAS antagonists) – were identified if their specific drug 
class proportion of days covered (PDC) was < 80% in a 12-month baseline period 
(2010Q4-2011Q3). Letters were mailed to their prescribers suggesting they discuss 
potential adherence barriers with their patients. Post-mailing PDC was calculated 
during a 12-month follow-up period after the mailing date. Members were included 
if they were age 18+, had 2 or more fills within the drug class, and were continu-
ously enrolled in the prescription drug plan during the baseline and follow-up peri-
ods. A historical control cohort was constructed using the same eligibility criteria 
as applied to the intervention cohort but no letter was mailed to the prescribing 
physicians. Multivariate logistic regression was used to model post-mailing adher-
ence (PDC≥ 80%), adjusting for age, gender, zip code level income, education and 
race variables. Analyses were conducted separately for each drug class. Results: 
Final analyzable members included 21,044 (Intervention= 10,707; Control= 10,337) 
for antidiabetics, 106,829 (Intervention= 53,957; Control= 52,872) for statins, and 
73,560 (Intervention= 36,706; Control= 36,854) for RAS antagonists. The baseline 
PDCs between the intervention and control cohorts were not statistically differ-
ent for all the three drug cohorts. Adjusted logistic regression results indicate the 
prescriber mailing was associated with significant adherence improvement, odds 
ratio (OR) 1.11 (95% confidence interval [CI], 1.05-1.18), OR 1.16 (95% CI, 1.13-1.19), 
and OR 1.07 (95% CI, 1.03-1.10) within the antidiabetic, statin and RAS antagonist 
drug classes, respectively. cOnclusiOns: Health plans should consider utilizing 
prescriber mailings in efforts to improve medication adherence for chronic diseases.
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Objectives: To analyze patient compliance towards their prescribed medication 
and to evaluate the patient knowledge regarding use of drugs. MethOds: The study 
was conducted in a tertiary care hospital in Pakistan. A random sample of 200 
patients was selected. The questionnaire was administered by trained interviewers 
in the Urdu language for ease of understanding by the patient. The questionnaire 
extracted information regarding patient demographics, life style (smoking, drink-
ing, physical activities), awareness about and characteristics of hypertension and 
anti-hypertensive treatment and factors that, in the patient’s views, encouraged or 
discouraged the patient’s drug taking behavior. Results: According to analysis, 81% 
patients were from urban areas and 19% patients were from rural areas. Most (71%) 
of the patients belonged to the age group of 40-50 years. Majority of the affected 
persons were male i.e. 70%, whereas females were 30%. The patients with history of 
CVS disorders in their families were 36%. It was found that 36% of the patients were 
smokers, 2% were drinkers and 75% had no physical activity in routine. The patients 
went for regular follow up of their blood pressure were 38.5% and 53% of the patients 
had regular lab tests during their treatment. It was found that 74.5% of patients used 
to take medication on time while 64% stopped their medication when they felt bet-
ter. The major reason (27.5%) for not taking medication was found to be the use of 
alternative medicines while 60% patients tried to clarify their doubts about therapy. 
Majority of patients (81.5%) followed precautionary measures, 21% patients used 
different reminders and 30.5% patients had difficulty in taking their medication. 
On felling worse 40% of the patients stopped taking medication. cOnclusiOns: 
There is need for educational intervention and patient counseling to understand 
the importance of compliance for this disease.
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Objectives: Single pill combinations (SPC) are associated with improved adher-
ence and persistence in hypertensive (HTN) populations. The evidence is not 
available for three drug SPC Exforge HCT. This study investigated if Exforge HCT 
is associated with improved 12-month persistence and adherence in adult hyper-
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tensive (HTN) patients. MethOds: The study included adults (18 yrs. or older) 
HTN patients covered by commercial and Medicare Supplemental insurance in the 
Truven MarketScan database with an HTN diagnosis between October 2009 and 
December 2011. At least two filled prescriptions for Exforge HCT or two periods 
of minimum 15 days of concurrent use of amlodipine, valsartan and hydrochlo-
rothiazide (FC cohort) were required. Patients were continuously enrolled at least 
12 months before and 12 month after the index prescription and had valsartan 
initial dose of 160 or 320 mg/day. Adherence was measured with proportion of days 
covered (PDC) and medication possession ratio (MPR). Persistence was defined as 
no treatment gap greater than 30 days. Chi-Square tests and independent sample 
t-tests were used after adequate propensity score matching (PSM) (absolute stand-
ardized differences < 0.1) using demographics, comorbidities, pre-index health 
care utilization , pre-index costs and valsartan initial dose. Results: Exforge 
HCT patients (N= 9,221) had better unadjusted outcomes compared to FC patients 
(N= 1,884): higher MPR (81.6% vs 77.0%), PDC (70.0% vs 60.6%) and persistence 
(42.7% vs 23.6%) (all p< 0.0001). After risk-adjustment with PSM, Exforge HCT 
patients also exhibited better outcomes compared to FC patients: higher adher-
ence (85.7% vs 77.0%), higher PDC (73.8% vs 60.6%) and persistence (46.8% vs 23.6%) 
(all p< 0.0001). More patients had MPR> 80% in the Exforge HCT cohort (72.9% vs 
57.5%, p< 0.0001). cOnclusiOns: Real-world data indicate that Exforge HCT is 
associated with improved adherence and persistence compared to amlodipine/
valsartan/hydrochlorothiazide FC. These data should be considered by stakehold-
ers engaged with optimizing outcomes of HTN patients.
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Objectives: Diet and exercise along with the pharmacological treatment are 
required for an adequate control of blood pressure among hypertensive patients. 
The aim of this study is to identify the drug treatments prescribed and attitudes 
and factors associated with the adherence to these indications. MethOds: Socio-
demographic and drug treatment information of hypertensive patients aged 20 years 
and older was obtained from an institutional health survey, Encoprevenimss 2010. 
Statistical relationships between socio-demographic variables and adherence to diet 
and exercise were tested. Two binary logistic regression models were constructed to 
measure the impact of personal attitudes and social and demographic variables on 
the decision of the patient whether to follow these recommendations. Results: 
Captopril was the leading prescribed drug (31.63%), followed by enalapril (22.45%) 
and metopropol (13.58%). The main combination of drugs recommended was cap-
topril with metopropol. Additionally to the pharmacological treatment, 32.47% and 
23.59% of the patients reported full adherence to the diet and exercise indications 
respectively, 24.04% and 15.78% partially complied and 11.03% and 16.63% did not 
comply. At 5% level of significance, statistically significant relationships were found 
between diet and exercise with gender (p-vale= 0.007, p-value= 0.000), as well as 
with age groups (p-value= 0.000). The results from the logistic regressions show 
that patients with lack of interest about the importance of diet and exercise in 
their treatment are less likely to adhere to these recommendations. Furthermore 
individuals that have their blood pressure monthly monitored compared with those 
who make it annually, are two times more likely to comply with diet and 1.25 times 
with exercise. Patients at a higher level of education and at older ages have a greater 
probability to follow these indications. cOnclusiOns: Health campaigns and pro-
grams to encourage patients to monitor frequently their blood pressure are desirable 
in order to improve compliance to non-pharmacological suggestions.
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Objectives: Patients with hypertension in Japan report poor health outcomes, 
particularly quality of life. Although quality of life can be improved with advances 
in treatment, there are other modifiable factors which could also be examined 
as potential targets for intervention. This study investigated the association of 
medication adherence and health behaviors with health status. MethOds: Data 
from the Japan 2012 National Health and Wellness Survey (NHWS) were used 
(N= 30,000). Only respondents taking a medication for their hypertension were 
included (n= 3,611). Smoking status, exercise behavior, obesity (measured using 
body mass index), alcohol use, and medication adherence (measured using the 
Morisky Medication Adherence Scale [MMAS-8]) were used as predictors of health 
status (measured using the Short Form-36v2) controlling for demographics and 
comorbidities. Results: A total of 67.2% respondents were male; the mean age 
was 63.11 years. Most patients had a history of smoking (19.6% were current smok-
ers and 36.7% were former smokers) and nearly 30% consumed alcohol daily. On 
average, patients exercised less than 7 days per month and a third of patients were 
either overweight (27.6%) or obese (5.8%). When examining items of the MMAS-8, 
forgetfulness was the most common reason for non-adherence (forgetting, 47.8%; 
difficulty remembering, 28.9%; forgetting when traveling/leaving home, 20.7%). 
Controlling for demographics and comorbidities, the strongest predictors of health 
status were with obesity (b = -2.68 for PCS), exercise (b = 0.14 for PCS), and forget-
ting medications (-1.08 for PCS) (all p< .05). cOnclusiOns: Significant associations 
between adherence and health behaviors and health status were observed. Although 
cross-sectional associations may not translate to causal relationships, these results 
suggest that improved exercise and weight reduction may result in notable health 
status improvements, aside from their well-known clinical benefits. Interventions 
which make it easier for patients to remember their medications could also have 
health status benefits.
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Objectives: Dyslipidemia has been associated with decrements in health sta-
tus among patients in Japan. Aside from improved treatment regimens, health 
behavior and adherence interventions may also help to improve patient outcomes. 
This study investigated the association of adherence and health behaviors with 
health status among patients with dyslipidemia in Japan. MethOds: Data from 
the Japan 2012 National Health and Wellness Survey (NHWS) were used (N= 30,000). 
Only respondents who were using a prescription medication for dyslipidemia 
were included (n= 1,510). Smoking, exercise behavior, obesity (measured using 
body mass index), alcohol use, and medication adherence (measured using the 
Morisky Medication Adherence Scale-8) were self-reported by the patient and used 
as predictors of health status (measured using the physical component summary 
[PCS] and mental component summary of the Short Form-36v2) controlling for 
demographics and comorbidities. Results: The respondents had a mean age of 
61.4 years; slightly more than half (53.2%) were male. Most patients had a his-
tory of smoking (18.6% were current smokers and 33.9% were former smokers) 
and patients exercised a mean of 7.1 days per month. Nearly 30% of patients 
were either overweight (23.9%) or obese (5.0%). Intentional non-adherence was 
high with 52.50% of patients cutting back or stopping their medication on their 
own. Forgetfulness was also common (forgetting, 35.7%; not taking medication in 
the past two weeks, 25.9%; difficulty remembering, 18.3%). Controlling for demo-
graphics and comorbidities, the strongest predictors of health status were with 
smoking (b = -1.04 for PCS), obesity (b = -3.51 for PCS), exercise (b = 0.14 for PCS), 
and forgetting medications (b = -0.75 for PCS) (p< .05). cOnclusiOns: Smoking 
cessation, improved exercise, and weight reduction may all result in significant 
health status improvements among patients with dyslipidemia. Interventions 
which make it easier for patients to remember their medications could have health 
status benefits in this population.
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Objectives: The prevalence of the clustering of cardiometabolic risk factors 
(CMSRFs) namely hypertension, obesity, hyperlipidemia and diabetes is increasing. 
But there is limited recent information on prevalence, demographic characteris-
tics, quality of life and health care expenditures. MethOds: Full year consoli-
dated data of the nationally representative Medical Expenditure Panel Survey 
was used (2009-2010). Many similar clinical conditions coded by the International 
Classification of Diseases (ICD-9-CM) diagnostic code are assimilated together to 
form Clinical Classification Categories (CCC). CCCs were used to identify patients 
with hyperlipidemia and hypertension whereas the interview component was 
used to identify patients with obesity and diabetes. CMS patients were defined 
as patients diagnosed with obesity and any two conditions among hypertension, 
hyperlipidemia and obesity. Prevalence of CMS, quality of life, workdays missed 
and total health care expenditures were determined among patients. Results: 
The prevalence of CMS was found to be 0.92% with the weighted frequency of 
CMS resulting to 2,848,683. Among the quality of life variables, most CMS patients 
reported having little interest in things ‘all the time’ (61.6%). They felt calm (47.1%), 
faced difficulty climbing stairs (35.6%) and walking steps (30%) and experienced 
pain (30%) ‘most of the times’. They ‘sometimes’ faced health limitations (40%), 
had lot of energy (33.7%) and accomplished less due to physical problems (25.5%). 
Most accomplished less (41%), had work limitations ‘none of the time’ (30.3%) 
and faced difficulty standing ‘little of the times’ (33.7%). 37.8% rated their SF-12 
evaluated general health as fair. The total number of workdays missed reported 
by CMS patients were ~3.5 times as compared to patients without CMS (5.12 vs 
1.42). The weighted mean total health care expenditures for CMS patients was 
$5128 vs $492 for those without CMS. cOnclusiOns: The prevalence of CMSRFs 
is increasing alarmingly. They have a detrimental effect on quality of life, work 
productivity and health care expenditures.
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Objectives: The aims of this study were to compare patient outcomes associ-
ated with TSOAC and warfarin in terms of quality of life (QoL). MethOds: We 
conducted a prospective, cross-sectional cohort study in an inner-city population 
treated with warfarin or a TSOAC for more than 3 months. The Duke Anticoagulation 
and Satisfaction Scale (DASS) was used to assess the anticoagulation-related QoL. 
Multivariate linear regression analysis was conducted to evaluate the association 
between TSOAC and QoL, adjusted for potential confounders. Results: A total 
of 138 consecutive patients were enrolled in the study, 73 in the warfarin group 
and 65 in the TSOAC group. Patients treated with a TSOAC were older (63.2±16.1 
vs. 54.9±16, p= 0.002), more likely to be white (33.9% vs.6.9%, p< 0.001), had higher 
education level (4 year college degree or higher, 34.4% vs. 9.6%, p= 0.004), and higher 
annual income (> $30,000, 75.7% vs 35%, p< 0.001), compared with warfarin treated 
patients. Patients treated with TSOAC, reported lower rates of bleeding or throm-
boembolism leading to emergency department visits or hospitalizations during 
the preceding twelve months of therapy, compared with warfarin treated patients 
(13.9% vs. 32.9%, p= 0.01). However, patients on TSOAC reported a higher rate of side 
